Retinal Physician April 2025
APRIL 2025 VOLUME 22 | NUMBER 3 www.retinalphysician.com The Promise of TKIs Tyrosine kinase inhibitors may represent a new era for treatment of wet AMD and diabetic retinopathy. OMAR SAEED, DO, MPH • VEERAL S. SHETH, MD, MBA, FASRS Second-Generation Anti-VEGF Agents for Neovascular AMD SCOTT D. WALTER, MD, MSC, FASRS • SHARON FEKRAT, MD, FACS, FASRS Novel Th erapeutics for Neovascular AMD JUSTIN MUSTE, MD • KATHERINE E. TALCOTT, MD Treating Ophthalmic Artery Stenosis in Patients With AMD MARIO SARAVIA,
